ClinicalTrials.gg
Status unknownNCT05387148Updated Jun 3, 2022

The Efficacy and Neurobehavioural Mechanism of Cannabidiol (CBD) for Alcohol Dependence

A Phase 2 interventional study of Cannabidiol (CBD) and Placebo in Alcohol Use Disorder (AUD), sponsored by South West Sydney Local Health District. Status unknown at 1 site in Australia. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-06-03.

Sponsored by South West Sydney Local Health District · Phase 2, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified May 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies testing cannabidiol in Alcoholism — 4 open to participants now, 4 under way, 2 of them phase 3. Cannabidiol · Alcoholism.

Planned enrollment
11th of 12
20 · median 49
Started
2022
with 1 other
Phase 2
5 of 12
2 open now
Registered
7th of 12
by date
Lead sponsor
2 of 12
South West Sydney Local Health District

Among the 12 studies testing cannabidiol in Alcoholism, this one is the 11th largest by planned enrollment, is one of 2 that started in 2022, is one of 5 in phase 2, and was the 7th registered.

Alcoholism

1,679 studies on the registry are indexed under Alcoholism; 333 are open to participants now.

Browse Alcoholism studies →

Open to participants now

4 of the 12 studies testing cannabidiol in Alcoholism are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

About cannabidiol

Cannabidiol: first FDA approval 2018 (EPIDIOLEX), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 238 Alcoholism studies recruiting now, 85 (36%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing cannabidiol in Alcoholism, or all of them as a file.
02

Study summary

The study will explore the psychophysiological and neurobiological and mechanisms of CBD in participants with alcohol use disorder

Read the detailed description

New treatment strategies for treating symptoms of alcohol dependence are urgently needed. Although alcohol related disorders are a leading cause of preventable death in Australia, their treatment is generally not evidence based. Cannabidiol (CBD) may serve as a novel pharmacotherapeutic due to its anxiolytic, anti-epileptic, neuro-protective, antioxidant and neuroprotective properties as well as a particularly safe side effect profile. Further, CBD has been shown to modulate drug craving and seeking behaviours.

This project will examine whether CBD exerts an effect on cue-induced craving by reducing activation in areas of the brain responsive to alcohol cues in comparison to a placebo. This study will use functional magnetic resonance imaging (fMRI) to examine activity in the brain while participants are exposed alcohol related cues and magnetic resonance spectroscopy (MRS) to determine levels of neurotransmitters that may be responsible for craving. In addition, we aim to investigate the effects of CBD on autonomic nervous system parameters associated with alcohol withdrawal symptoms and anxiety, such as heart rate variability and skin conductance. Additionally, clinical outcome measures will be taken to investigate CBDs influence on drinking, sleep

This project uses a randomised, double blind, crossover design with 800mg CBD vs matched placebo. The dosing paradigm will consist of one dose per day for three days per arm with a 18 days washout period in-between arms.

03

Conditions studied

  • Alcohol Use Disorder (AUD)

Keywords

  • Alcohol Withdrawal
  • Alcohol-Related Disorders
  • Substance-Related Disorders
  • Mental Disorders
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients between ages of 18 and 65 meeting criteria for current alcohol use disorder
  • Adequate cognition and English language skills to give valid consent and complete research interviews;
  • A BrAC reading of 0.00
  • Must have a stable residence and be able to identify an individual who could locate subject if needed
  • Provision of

Exclusion criteria

Exclusion Criteria:

  • Active major psychological disorder associated with psychosis, significant suicide risk
  • Pregnancy or lactation - women shall be advised to use reliable for the duration of drug therapy and a urine pregnancy test will be performed where necessary;
  • Dependence on any substance other than nicotine (eg methadone)
  • Diagnosis of epilepsy, and/or current use of anti-epileptic drugs (AED)
  • Liver failure with jaundice or prolonged above 1.3
  • Medical complications such as liver failure, cardiac ischemia or conduction abnormalities, renal impairment or unstable elevated vital signs (systolic blood pressure > 180, diastolic blood pressure > 120 or heart rate > 150)
  • Severe cognitive impairment or insufficient English or literacy to complete study processes
  • Concurrent use of drugs potentially exacerbated by CBD via CYP3A5 including cardiac medication (e.g. betablockers, calcium channel blockers and statins), macrolides and recent antihistamine use.
  • Claustrophobia;
  • Extreme obesity;
  • Previous brain surgery;
  • Ever employed as a machinist, a welder or a metal worker;
  • Metal items such as pacemakers; aneurysm clips in the brain; metal dental implants; metallic fragments in the eye or anywhere else; insulin pump; metal implants; hearing aid or a prosthetic device.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Cannabidiol (CBD)

    For a total of three days, so that both study participants and staff are blind to treatment condition

    Drug: Cannabidiol (CBD)

  • Placebo comparator
    Placebo

    For a total of three days, so that both study participants and staff are blind to treatment condition

    Drug: Placebo

Interventions

  • DrugCannabidiolStudies of CannabidiolCannabidiol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Four 200mg soft gel capsules of Cannabidiol (CBD) will be taken orally daily for a total of 3 days.

  • DrugPlacebo

    The placebo will be identical in appearance, taste, and composition except for the active ingredient of pure CBD. So, four 200mg soft gel capsules of the placebo will be taken orally daily for a total of 3 days.

06

What researchers measure

Primary outcomes

  1. Changes in High Frequency Heart Rate Variability

    To assess whether acute ingestion of CBD can modulate heart rate variability when responding to alcohol cues compared to neutral cues

    Time frame: 22 days

  2. Changes in Skin Conductance Levels

    To assess whether acute ingestion of CBD modulates skin conductance levels when responding to alcohol cues compared to neutral cues

    Time frame: 22 days

  3. Changes in Brain Activation

    To assess whether acute ingestion of CBD can attenuate brain activation via blood oxygen level dependent (BOLD) in areas associated with alcohol cue-elicited craving measured by an fMRI machine

    Time frame: 22 days

  4. Changes in Neurotransmitter levels in the Brain

    To assess whether CBD treatment leads to changes in brain levels of the neurotransmitters: glutamate, gamma-aminobutyric acid (GABA), N-acetylaspartate (NAA) and glutathione (GSH)

    Time frame: 22 days

  5. Heavy Drinking Days

    Reduction in Heavy Drinking Days (HDD; defined as 4 or more drinks in a day for women and five or more drinks in a day for men). This will be measured by the Timeline Follow Back.

    Time frame: Up to 43 days

  6. Absence of any Heavy Drinking Day

    Measured by Timeline Follow Back

    Time frame: Up to 43 days

  7. Mean Alcohol Consumption per Drinking Day

    Measured by Timeline Follow Back

    Time frame: Up to 43 days

  8. Alcohol Dependence Severity

    Measured by the Alcohol Dependence Scale. The minimum score is 0 and the maximum score is 47. A higher score indicates more severe dependence.

    Time frame: Baseline

  9. Alcohol Craving

    As measured by the Penn Alcohol Craving Scale (PACS), which measures the amount of time spent thinking and craving for alcohol, difficulty in resisting consumption of alcohol if present and hypothetical pleasure associated with consumption of alcohol. This scale has a minimum score of 0 and a maximum score of 6. A higher score indicates greater levels of craving.

    Time frame: Up to 43 days

Secondary outcomes

  1. Changes in Alcohol Craving

    To assess whether acute ingestion of CBD can modulate subjective measures of alcohol cue elicited craving. This will be measured during the fMRI scan using the Visual Analogue Scale. This scale will assess alcohol craving, thirst and anxiety.

    Time frame: 22 days

  2. Changes in Alcohol Craving in response to alcohol cues

    To assess whether acute ingestion of CBD can modulate subjective measures of alcohol cue elicited craving. This will be measured before and after the fMRI scan using the Alcohol Urge Questionnaire (AUQ). This Questionnaire consists of 8 questions that are scored on a Likert scale of 7 points. Two of the questions are reversed scored. Total score is computed by averaging the item scores. A greater score indicates greater craving.

    Time frame: 22 days

  3. Changes in Positive and Negative Mood States

    To assess whether acute ingestion of CBD can modulate subjective measures of positive and negative mood states following alcohol cues. This will be measured before and after the fMRI scan using the Positive and Negative Affect Schedule (PANAS).

    Time frame: 22 days

  4. Changes in Anxiety

    Measured by cumulative scores on the DASS-21 Anxiety Scale. This scale has a minimum score of 0 and maximum score of 21. A higher score indicates more anxiety.

    Time frame: Up to 43 days

  5. Changes in Depression

    Measured by cumulative scores on the DASS-21 Depression Scale. This scale has a minimum score of 0 and maximum score of 21. A higher score indicates greater depression.

    Time frame: Up to 43 days

  6. Changes in Stress

    Measured by cumulative scores on the DASS-21 Stress Scale. This scale has a minimum score of 0 and maximum score of 21. A higher score indicates more stress.

    Time frame: Up to 43 days

  7. Sleep Disturbances

    As measured by the ISI (Insomnia Severity Index). This Index has a minimum score of 0 and a maximum score of 28. The higher the score indicates more severe insomnia.

    Time frame: Up to 43 days

  8. Sleep Disturbances

    To assess whether acute ingestion of CBD has any impact of sleep. This will be measured by an Actiwatch. The Actiwatch records motion and light to determine information about participants sleep and wake patterns. The participants will wear this watch for 48 hours on two separate occasions.

    Time frame: 22 days

  9. Changes in Tension Reduction Alcohol Expectancies

    To assess whether CBD treatment can reduce participants need to use alcohol to attenuate tension states (such as anxiety) as measured by the Tension Reduction subscale of the Alcohol Expectancy Questionnaire. Higher scores indicate greater reliance on alcohol to reduce tension/ anxiety.

    Time frame: Up to 43 days

  10. Lifetime Consequences related to Drinking

    To examine the adverse consequences a participant has experienced in their lifetime due to alcohol abuse in five areas: Interpersonal, Physical, Social, Impulsive, and Intrapersonal. This is measured using the Drinker Inventory of Consequences Lifetime Edition (DrInC-2L). Higher scores indicate more consequences.

    Time frame: Baseline

  11. Recent Consequences related to Drinking

    To examine the adverse consequences a participant has experienced in the last 3 months due to alcohol abuse in five areas: Interpersonal, Physical, Social, Impulsive, and Intrapersonal. This is measured using the Drinker Inventory of Consequences Recent Edition (DrInC-2R). Higher scores indicate more consequences.

    Time frame: Baseline

  12. Behavioural Inhibition/Avoidance Scales

    The BIS/BAS Scale is a 20-item self-report questionnaire designed to measure two motivational systems: the behavioral inhibition system (BIS), which corresponds to motivation to avoid aversive outcomes, and the behavioral activation system (BAS), which corresponds to motivation to approach goal-oriented outcomes.

    Time frame: 22 days

  13. Obsessive Compulsive Drinking

    To assess an individuals obsessive thoughts about alcohol use and compulsive behaviours towards drinking as measured by the Obsessive Compulsive Drinking Scale. Six of the questions measure to obsession and eight of the questions measure compulsivity. Higher scores on these subscales indicate more obsession and compulsion, respectively.

    Time frame: 22 days

  14. Self-Confidence to Remain Abstinent

    To measure an individual's self-confidence in avoiding alcohol through the Alcohol Abstinence Self-Efficacy Scale (AASE). There are 20 questions and each is scored from 0 to 4. Higher scores on this scale indicate more self-confidence.

    Time frame: 22 days

  15. Intolerance of Uncertainty

    To assess an individual's reactions to situations that are ambiguous, the consequences of being uncertain, and attempts the individual might make to control the future. This will be measured through the Intolerance of Uncertainty Scale (IUS). This scale includes 27-items that are scored on a Likert scale (1 - Not at all characteristic of me to 5 - entirely characteristic of me). All scores are summed up and a higher score indicates greater inability to deal with uncertainty.

    Time frame: 22 days

  16. Impulsivity

    To assess an individual's impulsivity across four domains: urgency, lack of premeditation and perseverance, and sensation seeking. This will be measured through the Impulsivity Scale (UPPS). Greater scores on this scale indicate greater impulsivity.

    Time frame: 22 days

  17. Alcohol Withdrawal

    To assess an individual's severity of alcohol withdrawal through the Clinical Institute Withdrawal Assessment of Alcohol Scale - Revised (CIWA-Ar). Greater scores on this scale indicate the participant is experiencing greater alcohol withdrawal symptoms.

    Time frame: 22 days

  18. Approach and Avoidance towards Alcohol

    To assess an individual's automatic action tendencies (either approve or avoid) towards alcohol. This will be measured through the Approach Avoidance Task (AAT).

    Time frame: Up to 43 days

  19. Response Time and Visuospatial Skills

    To assess an individual's response time and visuospatial skills through the Trail Making Test Part A (TMT-A).

    Time frame: Up to 43 days

  20. Set-shifting Flexibility, Attention, and Inhibition

    To assess an individual's set-shifting flexibility, attention and inhibition through the Trail Making Test Part B (TMT-B).

    Time frame: Up to 43 days

  21. Risk/Reward Taking Behaviour

    To assess an individual's risk taking behaviour measured through the Balloon Analogue Risk Task (BART).

    Time frame: Up to 43 days

  22. Decision Making

    To assess an individual's decision making skills measured through the Columbia Card Task (CCT).

    Time frame: Up to 43 days

  23. Response Inhibition

    To assess an individual's ability to inhibit prepotent responses measured through the Stroop task.

    Time frame: Up to 43 days

  24. Working Memory Capacity to Update Information

    To assess an individual's capacity to update working memory information measured through the N-back task.

    Time frame: Up to 43 days

  25. Working Memory Capacity to Shift Information

    To assess an individual's capacity to shift between two tasks measured by the Number Letter task.

    Time frame: Up to 43 days

  26. Markers of neuroinflammation

    As measured by differences in blood sampling levels of glutathione.

    Time frame: Up to 43 days

  27. Markers of Stress

    As measured by differences in blood sampling levels of cortisol. This will be measured at rest, before the fMRI scan and following the fMRI scan.

    Time frame: Up to 43 days

07

Study locations

1 of 1 sites recruiting
  • Drug Health Services, Royal Prince Alfred Hospital
    Sydney, New South Wales 2050, Australia
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2022; primary completion for Jun 2023, 12 months later.

Of 123 non-industry phase 2 interventional studies under Alcoholism, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 59. This study's planned 12 months is below that.

Counting every sponsor, half of 135 studies reached it within 33 months; a quarter within 21 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2022
First posted
May 24, 2022
StartEst.
Jun 2022
Primary completionEst.
Jun 2023
CompletionEst.
Jun 2024
Last update
Jun 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05387148
Lead sponsor
South West Sydney Local Health District
Collaborators
University of Sydney, Lambert Initiative for Cannabinoid Therapeutics
Responsible party
Kirsten Morley BPsych MPH PhD (Associate Professor Kirsten Morley, University of Sydney) — Principal investigator
First posted
May 24, 2022
Start date
Jun 2022 (estimated)
Primary completion
Jun 2023 (estimated)
Completion
Jun 2024 (estimated)
Last update
Jun 3, 2022

Study contacts

Kirsten Morley, PhD
Contact
kirsten.morley@sydney.edu.au
+61295153636

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabidiol

Start the discussion